BLAY, J.Y., P. CASALI, C. BOUVIER, C. DEHAIS, I. GALLOWAY, J. GIETEMA, Jana HALÁMKOVÁ, N. HINDI, A. IDBAIH, E. KINLOCH, H.J. KLUMPEN, T. KOLAROVA, K. KOPECKOVA, J. LOVEY, M. MAGALHAES, K. OSELIN, S. PIPERNO-NEUMANN, A. RAVNSBAEK, M. ROGASIK, A. SAFWAT, S. SCHEIPL, M. SECKL, J. TAYLOR, M. TEMNYK, A. TRAMA, M. URBONAS, M. WARTENBERG and A. WEINMAN. European Reference Network for rare adult solid cancers, statement and integration to health care systems of member states: a position paper of the ERN EURACAN. ESMO OPEN. LONDON: BMJ PUBLISHING GROUP, 2021, vol. 6, No 4, p. 1-10. ISSN 2059-7029. Available from: https://dx.doi.org/10.1016/j.esmoop.2021.100174.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name European Reference Network for rare adult solid cancers, statement and integration to health care systems of member states: a position paper of the ERN EURACAN
Authors BLAY, J.Y. (guarantor), P. CASALI, C. BOUVIER, C. DEHAIS, I. GALLOWAY, J. GIETEMA, Jana HALÁMKOVÁ (203 Czech Republic, belonging to the institution), N. HINDI, A. IDBAIH, E. KINLOCH, H.J. KLUMPEN, T. KOLAROVA, K. KOPECKOVA, J. LOVEY, M. MAGALHAES, K. OSELIN, S. PIPERNO-NEUMANN, A. RAVNSBAEK, M. ROGASIK, A. SAFWAT, S. SCHEIPL, M. SECKL, J. TAYLOR, M. TEMNYK, A. TRAMA, M. URBONAS, M. WARTENBERG and A. WEINMAN.
Edition ESMO OPEN, LONDON, BMJ PUBLISHING GROUP, 2021, 2059-7029.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30230 Other clinical medicine subjects
Country of publisher Netherlands
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 6.883
RIV identification code RIV/00216224:14110/21:00124404
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.esmoop.2021.100174
UT WoS 000703610200044
Keywords (in Czech) ERN; European Reference Network; EU; European Union; EURACAN; ESMO; solid cancers;
Keywords in English ERN; European Reference Network; EU; European Union; EURACAN; ESMO; solid cancers;
Tags Excelence Science, INT, MU, operator, RIV
Tags International impact, Reviewed
Changed by Changed by: Bc. Hana Vladíková, BBA, učo 244692. Changed: 16/3/2022 11:04.
Abstract
A better understanding of the biology of rare cancers, an improved access to optimal diagnosis, to effective therapies, and to evidence-based treatment guidelines will all improve the outcome of patients with rare cancers. Still, disparities exist across Europe between countries and regions, with heterogeneous patient pathways, and different points of access contacted for initial health care management. Health migration issues also need to be addressed to reduce inequities in care for the European patient.
Links
LM2018128, research and development projectName: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Acronym: CZECRIN)
Investor: Ministry of Education, Youth and Sports of the CR
PrintDisplayed: 5/5/2024 08:58